- Home
- SPB vs PVLA Comparison
SPB vs PVLA Comparison
Compare SPB & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPB | PVLA |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPB | PVLA |
|---|---|---|
| Price | $88.92 | $144.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $82.40 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 339.6K | 276.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $1.85 | $104,350.18 |
| P/E Ratio | $41.40 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $29.59 |
| 52 Week High | $89.58 | $161.38 |
Technical Indicators
Market Signals| Indicator | SPB | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 56.59 |
| Support Level | $72.94 | $106.07 |
| Resistance Level | N/A | $156.28 |
| Average True Range (ATR) | 2.47 | 10.32 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 96.37 | 38.93 |
Price Performance
Historical ComparisonAbout SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.